علاج جدري القرود في المرضى ناقصي المناعة والمرض الشديد

References

• Those with severe disease (e.g., haemorrhagic disease, confluent lesions, sepsis, encephalitis, or other conditions requiring hospitalisation)
• Those who are immunocompromised (e.g., acquired immune deficiency syndrome with CD4 count <200 cells/µL leukaemia, lymphoma, generalised malignancy, solid organ transplantation, therapy with alkylating agents, antimetabolites, radiation, tumour necrosis factor inhibitors, high-dose corticosteroids, hematopoietic stem cell transplant recipient <24 months post-transplant or ≥24 months but with graft-versus-host disease or disease relapse, or having autoimmune disease with immunodeficiency as a clinical component).
• Paediatric populations, particularly patients younger than 8 years of age.
• Those with one or more complications (e.g., secondary bacterial skin infection; gastroenteritis with severe nausea/vomiting, diarrhoea, or dehydration; bronchopneumonia; concurrent disease or other comorbidities).
• If tecovirimat is unavailable, VIG is the next preferred option.
• Dose of 6000 Units/kg intravenous.
• Consider higher doses where the patient does not respond to the initial dose. Multiple and repeated treatments may be required.
• Bring VIG vials to room temperature prior to dosing. Administer 6000 U/kg intravenously through a dedicated intravenous line with the infusion rate of no greater than 2 mL/min.